MP High Court: Estranged Husband Entitled to Loss of Consortium Compensation After Wife’s Death || J&K & Ladakh HC: Claims under Roshni Act Void Ab Initio, Ownership Rights Null from Inception || Madras High Court Directs Expedited Trials in 216 Pending Criminal Cases Against MPs and MLAs || MP High Court: Allowing Minor to Drive Without Valid License Constitutes Breach of Insurance Policy || Punjab & Haryana High Court: Cyber Fraud Cases Uphold Public Trust, Cannot Be Quashed by Compromise || SC: Customer-Banker Relationship Based on Mutual Trust, Postmaster’s Reinstatement Quashed || Supreme Court: Company Buying Software for Efficiency and Profit Is Not a ‘Consumer’ under CPA || SC: Long Custody or Trial Delay Not Ground for Bail in Commercial Narcotic Cases if S.37 Unmet || Calcutta HC Disqualifies Politician Mukul Roy from Assembly under Anti-Defection Law || Supreme Court Bans Mining in and Around National Parks and Wildlife Sanctuaries

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :